Russian cancer vaccine shows early efficacy; Serbian patient slated for January dose
Published 1 d ago1 sourceEvidence: Reported
Eli Lilly has agreed to acquire Calytrix Bio, a blood cancer-focused biotech founded in 2025 by JP Morgan Life Sciences Private Capital, for $1.5 billion. The deal underscores Lilly's strategic pivot toward oncology, a departure from its traditional metabolic disease focus. Financial terms and regulatory timeline remain undisclosed, but the acquisition signals continued M&A activity in the biotech sector.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Published 1 d ago1 sourceEvidence: Reported
Published 2 d ago1 sourceEvidence: Reported
Published 3 d ago1 sourceEvidence: Unknown
Published 7 h ago2 sourcesEvidence: Reported
Published 1 d ago6 sourcesEvidence: Reported
Published 3 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported
Published 2 d ago2 sourcesEvidence: Reported